Developer docs
API playgroundTry for free, no card

Search company profiles

NeuPharma

Full company profile

uuid000pjnk

Namestring
NeuPharma
Legal namestring
Suzhou NeuPharma Co., Ltd.
Websiteurl
neupharma.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Suzhou NeuPharma Co., Ltd. (苏州润新生物科技有限公司), branded as NeuPharma, is a privately held clinical-stage biopharmaceutical company founded in 2019 in Suzhou BioBay, China, by returnee pharmaceutical industry professionals. The company develops innovative small-molecule anti-cancer therapeutics through a proprietary targeted drug discovery platform and currently operates four clinical-stage candidates: RX108, a Na+/K+-ATPase signal-transduction inhibitor in Phase II across glioblastoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma, with a Phase I oral tablet formulation (RX108-A) initiated in February 2025; RX208 (HLX208), a selective BRAF V600E inhibitor that received China NMPA Breakthrough Therapy Designation in April 2023 for BRAF V600E-mutated adult LCH/ECD and is licensed to Henlius for Greater China; RX518 (CK-101), a third-generation EGFR-TKI in Phase III for EGFR-mutated non-small cell lung cancer under collaboration with U.S.-based Checkpoint Therapeutics; and RX608, a dual BRAF V600/VEGFR inhibitor in Phase I as a Category 1 innovative drug. NeuPharma is led by President and CEO Dr. Qian Xiangping (钱向平).

The company's underlying technology centers on medicinal chemistry differentiated by novel mechanisms of action — most notably sodium-potassium ATPase inhibition for cell-cycle arrest and autophagy, and dual kinase blockade combining tumor-growth inhibition with anti-angiogenesis — supported by global intellectual property protection across multiple chemical scaffolds. NeuPharma's business model is pre-commercial and asset-partnership-driven: rather than building in-house sales infrastructure, the company out-licenses regional rights to industrial partners (Henlius for Greater China on RX208; Checkpoint Therapeutics for global RX518 development) and collaborates with academic institutions including Nanjing University, Shanghai Jiao Tong University, and Soochow University for upstream research. Revenue, where any exists, derives from upfront license payments, development and sales milestone fees, and royalties, with the disclosed Henlius agreement representing CNY 97.5 million upfront plus up to CNY 1.08 billion in potential milestones plus tiered royalties. No pricing model, customer base, or commercial product exists at present.

Short descriptiontext

NeuPharma is a privately held, Suzhou-based clinical-stage biopharmaceutical company developing four proprietary small-molecule anti-cancer drug candidates (RX108, RX208, RX518, RX608) across solid-tumor and rare-disease oncology indications, partnering regionally with Henlius and Checkpoint Therapeutics for development and commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
oncology drug development, small molecule therapeutics, targeted cancer therapy, clinical stage biopharmaceuticals, novel anti-cancer drugs
Industry1 code
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles1 record
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NeuPharma is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule anti-cancer drug candidates through a targeted drug discovery platform. Its pipeline comprises multiple novel-mechanism oncology assets (RX108 Na+/K+-ATPase inhibitor, RX208 BRAF V600E inhibitor, RX518 third-generation EGFR-TKI, and RX608 dual BRAF/VEGFR inhibitor) currently in Phase I–III clinical trials across solid tumors and hematological malignancies. The company monetizes pipeline assets via regional out-licensing and co-development partnerships with larger pharmaceutical companies rather than through direct commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Global market potential for corticorelin exceeds USD 1 billion annually with ~500,000 eligible patients worldwide
+1 more record
Product overview1 text field

NeuPharma is a clinical-stage biopharmaceutical company developing a portfolio of innovative small-molecule anti-cancer drugs. The pipeline includes: RX108 (Na+/K+-ATPase inhibitor in Phase II for multiple solid tumors including glioblastoma and HCC, also available as oral RX108-A tablets in Phase I); RX208 (BRAF V600E inhibitor licensed to Henlius for Greater China, in Phase II for LCH/ECD with breakthrough therapy designation); RX518 (third-generation EGFR-TKI in Phase III for NSCLC, developed with Checkpoint Therapeutics); and RX608 (dual BRAF/VEGFR inhibitor in Phase I). The company operates a proprietary targeted drug discovery platform focused on oncology.

Product and service5 records
1RX108
CategoryDrug Candidate
Description

Novel small-molecule inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with a multi-target anti-tumor mechanism (cell-cycle arrest, apoptosis, autophagy). Being developed for solid tumors including glioblastoma, hepatocellular carcinoma, head and neck cancer, and brain metastasis; currently in Phase II clinical trials.

2RX108-A Tablets
CategoryDrug Candidate (Oral Formulation)
Description

Oral tablet formulation of RX108 (Na+/K+-ATPase inhibitor) for treatment of locally advanced or metastatic solid tumors, with clinical focus on high-grade glioma and brain metastasis. Currently in Phase I clinical trials in China.

3RX208 (HLX208)
CategoryDrug Candidate
Description

Selective small-molecule BRAF V600E kinase inhibitor with proprietary novel chemical structure, exhibiting high bioavailability and anti-tumor efficacy. Being developed for BRAF V600E-mutant colorectal cancer, melanoma, and rare indications Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD). Licensed to Henlius for Greater China development and commercialization.

4RX518 (CK-101)
CategoryDrug Candidate
Description

Novel, potent, irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-sensitive mutations (exon 21 L858R and exon 19 deletion) and the EGFR T790M resistance mutation, with weak inhibition of wild-type EGFR. Developed for EGFR-mutant non-small cell lung cancer in collaboration with Checkpoint Therapeutics; in Phase III in China.

5RX608
CategoryDrug Candidate
Description

Dual-mechanism small-molecule inhibitor that simultaneously inhibits BRAF V600 kinase activity and VEGFR kinase activity, combining tumor growth inhibition with anti-angiogenesis. Targeted at advanced solid tumors with BRAF or RAS mutations. Currently in Phase I clinical trials in China.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Neupharma Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

Exclusive licensing agreement for corticorelin (C-PTBE-01) development and commercialization in Japan. Neupharma received exclusive rights to develop and commercialize the therapy for peritumoral brain edema. Curatis to receive upfront and milestone payments up to CHF 83.5 million plus royalties up to 20% on future Japanese sales. Neupharma planning to meet Japanese regulators (PMDA) in summer 2026 to discuss pivotal trial requirements.

biospace.com
2Henlius (复宏汉霖)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-29
Description

Exclusive licensing agreement granting Henlius rights to research, develop, produce, commercialize and sublicense RX208 (HLX208), a BRAF V600E inhibitor, in China (including Hong Kong, Macau and Taiwan). NeuPharma received CNY 97.5 million upfront payment and up to CNY 1.08 billion in development, registration and sales milestone payments plus sales royalties. Henlius is conducting Phase 2 clinical trial of RX208 for treatment of adult LCH and ECD with BRAF V600E mutation in China.

neupharma.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on development of RX518 (CK-101), a third-generation EGFR-TKI inhibitor. Clinical trials being conducted in USA, Australia and multiple countries. RX518 in Phase I/II trial under collaboration with Checkpoint Therapeutics.

4Nanjing University
Strategic tierMinorTypeOthers
Description

Academic partnership for research and development activities.

neupharma.com
5Shanghai Jiao Tong University
Strategic tierMinorTypeOthers
Description

Academic partnership for research and development activities.

neupharma.com
Strategic tierMinorTypeOthers
Description

Academic partnership for research and development activities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Precision oncology company developing targeted small-molecule therapies including KRAS and BRAF pathway inhibitors; comparable in targeting specific oncogenic mutations with novel chemistry.

2Hutchmed (Chi-Med)
TypeDirect peer
Description

Innovative Chinese oncology biopharma with proprietary small-molecule discovery platform; comparable business model of out-licensed and self-developed assets (e.g., surufatinib, savolitinib) serving similar global markets as NeuPharma.

TypeBroad incumbent
Description

Large Chinese-founded oncology biotech with global commercial footprint; comparable in that it develops innovative small-molecule and biologic oncology drugs, but operates at substantially greater scale with commercialized products.

4Plexxikon (Daiichi Sankyo)
TypeOthers
Description

Small-molecule kinase inhibitor discovery company (now part of Daiichi Sankyo) that pioneered vemurafenib (BRAF V600E); relevant historical comparator for novel BRAF V600E chemistry targeting similar oncology indications.

TypeBroad incumbent
Description

Innovative Chinese biopharma with oncology pipeline including small-molecule and biologic candidates; relevant comparator for Suzhou BioBay ecosystem companies and Chinese NMPA regulatory navigation.

TypeDirect peer
Description

NeuPharma's development partner for RX518 (CK-101); small US oncology biotech co-developing a third-generation EGFR-TKI in NSCLC, providing a direct peer in trial execution and out-licensing economics.

7Henlius (Shanghai Fosun)
TypeDirect peer
Description

NeuPharma's exclusive licensee for RX208 in Greater China; comparable Chinese oncology-focused biopharma with active clinical pipeline and cross-border deal-making experience.

TypeBroad incumbent
Description

China-based oncology-focused biopharma with both small-molecule and biologic pipeline; relevant comparator for Chinese oncology pipeline development, licensing strategy, and multi-asset approach.

TypeDirect peer
Description

Clinical-stage Chinese oncology company developing innovative small-molecule and biologic therapies; comparable pipeline-stage business model with similar dependence on out-licensing deals for commercialization.

10Genentech / Roche Oncology
TypeBroad incumbent
Description

Global oncology incumbent with vemurafenib (BRAF) and other targeted therapies; represents the competitive landscape and validation point for the BRAF V600E and EGFR spaces NeuPharma operates in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuPharma

Oncology Pharmaceuticalsneupharma.com

NeuPharma is a privately held, Suzhou-based clinical-stage biopharmaceutical company developing four proprietary small-molecule anti-cancer drug candidates (RX108, RX208, RX518, RX608) across solid-tumor and rare-disease oncology indications, partnering regionally with Henlius and Checkpoint Therapeutics for development and commercialization.

What NeuPharma does

Suzhou NeuPharma Co., Ltd. (苏州润新生物科技有限公司), branded as NeuPharma, is a privately held clinical-stage biopharmaceutical company founded in 2019 in Suzhou BioBay, China, by returnee pharmaceutical industry professionals. The company develops innovative small-molecule anti-cancer therapeutics through a proprietary targeted drug discovery platform and currently operates four clinical-stage candidates: RX108, a Na+/K+-ATPase signal-transduction inhibitor in Phase II across glioblastoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma, with a Phase I oral tablet formulation (RX108-A) initiated in February 2025; RX208 (HLX208), a selective BRAF V600E inhibitor that received China NMPA Breakthrough Therapy Designation in April 2023 for BRAF V600E-mutated adult LCH/ECD and is licensed to Henlius for Greater China; RX518 (CK-101), a third-generation EGFR-TKI in Phase III for EGFR-mutated non-small cell lung cancer under collaboration with U.S.-based Checkpoint Therapeutics; and RX608, a dual BRAF V600/VEGFR inhibitor in Phase I as a Category 1 innovative drug. NeuPharma is led by President and CEO Dr. Qian Xiangping (钱向平).

The company's underlying technology centers on medicinal chemistry differentiated by novel mechanisms of action — most notably sodium-potassium ATPase inhibition for cell-cycle arrest and autophagy, and dual kinase blockade combining tumor-growth inhibition with anti-angiogenesis — supported by global intellectual property protection across multiple chemical scaffolds. NeuPharma's business model is pre-commercial and asset-partnership-driven: rather than building in-house sales infrastructure, the company out-licenses regional rights to industrial partners (Henlius for Greater China on RX208; Checkpoint Therapeutics for global RX518 development) and collaborates with academic institutions including Nanjing University, Shanghai Jiao Tong University, and Soochow University for upstream research. Revenue, where any exists, derives from upfront license payments, development and sales milestone fees, and royalties, with the disclosed Henlius agreement representing CNY 97.5 million upfront plus up to CNY 1.08 billion in potential milestones plus tiered royalties. No pricing model, customer base, or commercial product exists at present.

NeuPharma firmographics

Firmographics
Name
NeuPharma
Legal name
Suzhou NeuPharma Co., Ltd.
Website
https://neupharma.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuPharma is a privately held, Suzhou-based clinical-stage biopharmaceutical company developing four proprietary small-molecule anti-cancer drug candidates (RX108, RX208, RX518, RX608) across solid-tumor and rare-disease oncology indications, partnering regionally with Henlius and Checkpoint Therapeutics for development and commercialization.
Ownership category
akta.pro rank

NeuPharma industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Oncology drug development
  • Small molecule therapeutics
  • Targeted cancer therapy
  • Clinical stage biopharmaceuticals
  • Novel anti-cancer drugs

Where NeuPharma is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Markets served

NeuPharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels2 records

NeuPharma product offering

Product offering

Core offering

NeuPharma is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule anti-cancer drug candidates through a targeted drug discovery platform. Its pipeline comprises multiple novel-mechanism oncology assets (RX108 Na+/K+-ATPase inhibitor, RX208 BRAF V600E inhibitor, RX518 third-generation EGFR-TKI, and RX608 dual BRAF/VEGFR inhibitor) currently in Phase I–III clinical trials across solid tumors and hematological malignancies. The company monetizes pipeline assets via regional out-licensing and co-development partnerships with larger pharmaceutical companies rather than through direct commercialization.

Product overview

NeuPharma is a clinical-stage biopharmaceutical company developing a portfolio of innovative small-molecule anti-cancer drugs. The pipeline includes: RX108 (Na+/K+-ATPase inhibitor in Phase II for multiple solid tumors including glioblastoma and HCC, also available as oral RX108-A tablets in Phase I); RX208 (BRAF V600E inhibitor licensed to Henlius for Greater China, in Phase II for LCH/ECD with breakthrough therapy designation); RX518 (third-generation EGFR-TKI in Phase III for NSCLC, developed with Checkpoint Therapeutics); and RX608 (dual BRAF/VEGFR inhibitor in Phase I). The company operates a proprietary targeted drug discovery platform focused on oncology.

Differentiator

Problem solved

Functional benefit

Products and services

  • RX108 Novel small-molecule inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with a multi-target anti-tumor mechanism (cell-cycle arrest, apoptosis, autophagy). Being developed for solid tumors including glioblastoma, hepatocellular carcinoma, head and neck cancer, and brain metastasis; currently in Phase II clinical trials.
  • RX108-A Tablets Oral tablet formulation of RX108 (Na+/K+-ATPase inhibitor) for treatment of locally advanced or metastatic solid tumors, with clinical focus on high-grade glioma and brain metastasis. Currently in Phase I clinical trials in China.
  • RX208 (HLX208) Selective small-molecule BRAF V600E kinase inhibitor with proprietary novel chemical structure, exhibiting high bioavailability and anti-tumor efficacy. Being developed for BRAF V600E-mutant colorectal cancer, melanoma, and rare indications Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD). Licensed to Henlius for Greater China development and commercialization.
  • RX518 (CK-101) Novel, potent, irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-sensitive mutations (exon 21 L858R and exon 19 deletion) and the EGFR T790M resistance mutation, with weak inhibition of wild-type EGFR. Developed for EGFR-mutant non-small cell lung cancer in collaboration with Checkpoint Therapeutics; in Phase III in China.
  • RX608 Dual-mechanism small-molecule inhibitor that simultaneously inhibits BRAF V600 kinase activity and VEGFR kinase activity, combining tumor growth inhibition with anti-angiogenesis. Targeted at advanced solid tumors with BRAF or RAS mutations. Currently in Phase I clinical trials in China.

Quantifiable outcome

  • Global market potential for corticorelin exceeds USD 1 billion annually with ~500,000 eligible patients worldwide
  • +1 more outcomes

Companies that use NeuPharma

Customer profile

Segments1 record

Ideal customer profiles2 records

NeuPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NeuPharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Neupharma Co., Ltd.coreStrategic or Co-development Partner · 11 March 2026Exclusive licensing agreement for corticorelin (C-PTBE-01) development and commercialization in Japan. Neupharma received exclusive rights to develop and commercialize the therapy for peritumoral brain edema. Curatis to receive upfront and milestone payments up to CHF 83.5 million plus royalties up to 20% on future Japanese sales. Neupharma planning to meet Japanese regulators (PMDA) in summer 2026 to discuss pivotal trial requirements.
  • Henlius (复宏汉霖)coreStrategic or Co-development Partner · 29 March 2021Exclusive licensing agreement granting Henlius rights to research, develop, produce, commercialize and sublicense RX208 (HLX208), a BRAF V600E inhibitor, in China (including Hong Kong, Macau and Taiwan). NeuPharma received CNY 97.5 million upfront payment and up to CNY 1.08 billion in development, registration and sales milestone payments plus sales royalties. Henlius is conducting Phase 2 clinical trial of RX208 for treatment of adult LCH and ECD with BRAF V600E mutation in China.
  • Checkpoint TherapeuticscoreStrategic or Co-development PartnerCollaboration on development of RX518 (CK-101), a third-generation EGFR-TKI inhibitor. Clinical trials being conducted in USA, Australia and multiple countries. RX518 in Phase I/II trial under collaboration with Checkpoint Therapeutics.
  • Nanjing UniversityminorOthersAcademic partnership for research and development activities.
  • Shanghai Jiao Tong UniversityminorOthersAcademic partnership for research and development activities.
  • Soochow University (苏州大学)minorOthersAcademic partnership for research and development activities.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

NeuPharma competitors and assessment

Company assessment

Broad incumbents

  • Mirati Therapeutics: Precision oncology company developing targeted small-molecule therapies including KRAS and BRAF pathway inhibitors; comparable in targeting specific oncogenic mutations with novel chemistry.
  • BeiGene: Large Chinese-founded oncology biotech with global commercial footprint; comparable in that it develops innovative small-molecule and biologic oncology drugs, but operates at substantially greater scale with commercialized products.
  • Junshi Biosciences: Innovative Chinese biopharma with oncology pipeline including small-molecule and biologic candidates; relevant comparator for Suzhou BioBay ecosystem companies and Chinese NMPA regulatory navigation.
  • Innovent Biologics: China-based oncology-focused biopharma with both small-molecule and biologic pipeline; relevant comparator for Chinese oncology pipeline development, licensing strategy, and multi-asset approach.
  • Genentech / Roche Oncology: Global oncology incumbent with vemurafenib (BRAF) and other targeted therapies; represents the competitive landscape and validation point for the BRAF V600E and EGFR spaces NeuPharma operates in.

Direct peers

  • Hutchmed (Chi-Med): Innovative Chinese oncology biopharma with proprietary small-molecule discovery platform; comparable business model of out-licensed and self-developed assets (e.g., surufatinib, savolitinib) serving similar global markets as NeuPharma.
  • Checkpoint Therapeutics: NeuPharma's development partner for RX518 (CK-101); small US oncology biotech co-developing a third-generation EGFR-TKI in NSCLC, providing a direct peer in trial execution and out-licensing economics.
  • Henlius (Shanghai Fosun): NeuPharma's exclusive licensee for RX208 in Greater China; comparable Chinese oncology-focused biopharma with active clinical pipeline and cross-border deal-making experience.
  • CStone Pharmaceuticals: Clinical-stage Chinese oncology company developing innovative small-molecule and biologic therapies; comparable pipeline-stage business model with similar dependence on out-licensing deals for commercialization.

Others

  • Plexxikon (Daiichi Sankyo): Small-molecule kinase inhibitor discovery company (now part of Daiichi Sankyo) that pioneered vemurafenib (BRAF V600E); relevant historical comparator for novel BRAF V600E chemistry targeting similar oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

NeuPharma social profiles

Digital presence

NeuPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuPharma leadership team

Management profile

Number of profiles

Profiles1 record

NeuPharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuPharma

What does NeuPharma do?

NeuPharma is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule anti-cancer drug candidates through a targeted drug discovery platform. Its pipeline comprises multiple novel-mechanism oncology assets (RX108 Na+/K+-ATPase inhibitor, RX208 BRAF V600E inhibitor, RX518 third-generation EGFR-TKI, and RX608 dual BRAF/VEGFR inhibitor) currently in Phase I–III clinical trials across solid tumors and hematological malignancies. The company monetizes pipeline assets via regional out-licensing and co-development partnerships with larger pharmaceutical companies rather than through direct commercialization.

Is NeuPharma a public or private company?

NeuPharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NeuPharma founded?

NeuPharma was founded in 2019. It employs 11 to 50 people.

Where is NeuPharma based?

NeuPharma is headquartered in Suzhou, China, in the Asia region.

Who are NeuPharma's main competitors?

Broad incumbents on record are Mirati Therapeutics, BeiGene, Junshi Biosciences, Innovent Biologics and Genentech / Roche Oncology. Direct peers are Hutchmed (Chi-Med), Checkpoint Therapeutics, Henlius (Shanghai Fosun) and CStone Pharmaceuticals. Plexxikon (Daiichi Sankyo) is listed as an others.

Does NeuPharma have an API?

No public API is recorded for NeuPharma.

What industry is NeuPharma in?

NeuPharma's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogStrongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)Curatis reported H1 2026 net sales of CHF 7.9m, up 51% year-over-year, with a loss narrowing to CHF -0.4m. Cash and cash equivalents rose to CHF 3.6m, and the company advanced its corticorelin program, including an exclusive Japan licence with Neupharma. It confirmed full-year revenue guidance of approximately CHF 15m.Pharmaceutical TechnologyCuratis, Neupharma sign development agreement for corticorelin in JapanSwitzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema in Japan, granting Neupharma exclusive rights to develop and commercialize the therapy. Curatis is set to receive upfront and milestone payments totalling up to SFr83.5 million ($107 million), along with royalties on future Japanese sales of up to 20%, with the initial launch planned for children and adolescents. The companies plan to meet Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in mid-2026 to discuss requirements for a registration-enabling study expected to commence in 2027, while Curatis continues parallel preparations for pivotal trials in Europe and the US.PharmiWeb.comCuratis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in JapanCuratis Holding AG and Neupharma Co., Ltd. have announced an exclusive licensing agreement for the development and commercialization of corticorelin (C-PTBE-01) to treat peritumoral brain edema (PTBE) in Japan, with Neupharma financing and conducting a pivotal clinical trial to support Japanese regulatory approval. Curatis will receive upfront and milestone payments totaling up to CHF 83.5 million, plus royalties of up to 20% on future Japanese sales. The drug targets a condition with no approved targeted therapies currently, with global market potential estimated to exceed USD 1 billion annually and an initial focus on children and adolescents in Japan.BioSpaceCuratis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in JapanCuratis Holding AG and Neupharma Co., Ltd. announced an exclusive licensing agreement for corticorelin (C-PTBE-01), an investigational drug for peritumoral brain edema, granting Neupharma exclusive rights to develop and commercialize the treatment in Japan. Under the agreement, Neupharma will finance and conduct a pivotal clinical trial in Japan while Curatis receives upfront and milestone payments of up to CHF 83.5 million plus royalties of up to 20% on future sales. The global market potential for corticorelin is forecasted to exceed USD 1 billion annually, with approximately 60,000 eligible patients in Japan and 500,000 worldwide.